Thomas Wegge
37Patents
7h-index
34Co-inventors
69Inventor score
Filing activity: Oct 1, 2004 → Jan 24, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8906847B2 | Prodrug comprising a drug linker conjugate | Chemistry; Metallurgy | 71 | Active |
| US9056126B2 | Hydrogel formulations | Performing Operations; Transporting | 57 | Active |
| US7968085B2 | Hydrogel formulations | Performing Operations; Transporting | 28 | Active |
| US7879588B2 | Protein-proteophore complexes | Emerging Cross-Sectional Technologies | 18 | Active |
| US8377917B2 | Polymeric prodrug with a self-immolative linker | Chemistry; Metallurgy | 13 | Active |
| US9511122B2 | Dry growth hormone composition transiently linked to a polymer carrier | Human Necessities | 10 | Active |
| US9272048B2 | PEGylated recombinant human growth hormone compounds | Chemistry; Metallurgy | 9 | Active |
| US9265723B2 | Long acting insulin composition | Emerging Cross-Sectional Technologies | 7 | Active |
| US10098930B2 | PEGylated Recombinant Human Growth Hormone Compounds | Chemistry; Metallurgy | 7 | Active |
| US10799563B2 | Polymeric hGH prodrugs | Chemistry; Metallurgy | 7 | Active |
| US9919033B2 | Dry growth hormone composition transiently linked to a polymer carrier | Human Necessities | 7 | Active |
| US10960053B2 | PEGylated recombinant human growth hormone compounds | Chemistry; Metallurgy | 5 | Active |
| US10682395B2 | Dry growth hormone composition transiently linked to a polymer carrier | Human Necessities | 5 | Active |
| US9872864B2 | Sustained release composition of prostacyclin | Human Necessities | 5 | Active |
| US11311604B2 | Controlled-release CNP agonists with low NPR-C binding | Emerging Cross-Sectional Technologies | 4 | Active |
| US9457066B2 | Prodrugs comprising an insulin linker conjugate | Emerging Cross-Sectional Technologies | 4 | Active |
| US11224661B2 | Controlled-release CNP agonists with increased NEP stability | Emerging Cross-Sectional Technologies | 4 | Active |
| US11793861B2 | PTH prodrugs | Human Necessities | 3 | Active |
| US11918628B2 | Controlled-release PTH compound | Human Necessities | 3 | Active |
| US11759504B2 | PTH compounds with low peak-to-trough ratios | Human Necessities | 3 | Active |
| US11857603B2 | PTH compounds with low peak-to-trough ratios | Human Necessities | 3 | Active |
| US11890326B2 | Controlled-release PTH compound | Human Necessities | 3 | Active |
| US9913912B2 | Carrier-linked prostanoid prodrugs | Human Necessities | 2 | Active |
| US8980242B2 | Aliphatic prodrug linker | Human Necessities | 2 | Active |
| US12133883B2 | Polymeric hGH prodrugs | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.